Assessing claims of misstatements about COVID-19 vaccine approval
Case study
Keystone experts supported clinical-stage biotechnology company in DNA vaccine shareholder lawsuit.
Keystone experts supported clinical-stage biotechnology company in DNA vaccine shareholder lawsuit.
Shareholders filed a class-action lawsuit against a biotechnology company that focuses on the discovery, development and commercialization of synthetic DNA products for treating cancers and infectious diseases. The lawsuit alleged that the company made false and misleading statements concerning the development of a COVID-19 vaccine.
Shareholders specifically claimed that the company misrepresented the vaccine development schedule, production capacity and regulatory approval timeline.
Keystone supported the biotech company's legal team with experts who analyzed and responded to the different legal complaints.
To learn more about this case or Keystone’s expertise in Healthcare and Life Sciences litigation and strategy, contact science@keystone.com.